PureRawz review

A site we could not read

PureRawz is a Knoxville, Tennessee research-chemical retailer that, by third-party account, has been operating since 2017 and sells peptides alongside SARMs and nootropics in vials, nasal, capsule and blend formats. We could not read it ourselves. Both purerawz.co and www.purerawz.co returned HTTP 403 during our check, and the Trustpilot page returned HTTP 451. Every site-level statement in this review is therefore unverified on the vendor’s own pages and drawn instead from the FDA letter, from Finnrick and from third-party review pages, some of them sponsored. Readers should weigh what follows accordingly, and the single most important fact is that the company holds an FDA warning letter dated September 8, 2025.

We attempted the homepage and product pages, read the warning letter on fda.gov, read Finnrick’s vendor and BPC-157 pages, and read the PeptideProtocolWiki entry, a peptidedossier.com review and a sponsored magazine review. Those are the sources for everything below, and where a fact comes from a third party we say so.

What is reported about testing, and by whom

Third-party reviews state that PureRawz names MZ Biolabs as its testing laboratory and posts batch-level certificates on product pages. Because the site did not load, we cannot confirm whether certificates are public, whether they are issued per lot, or whether they include HPLC, mass spectrometry, endotoxin or sterility data. The research-use disclaimer status is likewise unknown. We class third-party testing as limited: a lab is named, by others, and nothing can be checked.

Finnrick, an independent testing aggregator, reports that 13 of 29 classifiable tests passed, with BPC-157 at 2 passes and 2 failures in May 2025 and CJC-1295 scoring 23 percent. PeptideProtocolWiki, a community source, reports that some posted certificates contain outdated testing data that does not match the current batch. Both are third-party findings and we present them as such. Set side by side, they describe a vendor whose paperwork exists but whose independent results pass fewer than half the time, and whose paperwork may not describe the vial it is posted beside.

The warning letter, the company and what else is reported

The FDA issued a warning letter dated 2025-09-08 to PureRawz at 1404 Lakeshire Dr., Knoxville, TN 37922. It is available at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purerawz-715218-09082025. The letter concerns five products named in the letter that the agency considers unapproved new drugs, and the FDA stated that the “laboratory research” labeling did not change its assessment. The letter is also the only primary source for the company’s physical address, which third-party pages confirm.

Third-party sources date the company to 2017. A support email is published; no phone number is recorded. The Trustpilot score could not be verified because the page returned HTTP 451. Reddit presence is recorded as some, and PeptideProtocolWiki relays a PissedConsumer rating of 2.9. No price could be recorded from the site. Finnrick lists BPC-157 at a median of $12.26 per mg with no vial size, so no 5 mg benchmark exists, and the $100 free-shipping threshold comes from sponsored and wiki sources rather than from the vendor.

By third-party account the catalog spans peptides including BPC-157, TB-500, Tesamorelin, Ipamorelin, CJC-1295 and Melanotan II, several GLP-class products, and research chemicals such as RAD-140. The same sources describe US shipping with international options, domestic delivery in 5 to 12 business days and international in 8 to 17 days with country restrictions. Payments reported are card, crypto, Zelle, Venmo, ACH and PayPal, with Zelle and Venmo said to carry service fees. Returns reportedly exclude change-of-mind orders, cover damaged shipments and fulfillment errors, and generally require shipping insurance bought at checkout for lost or stolen orders. None of this was verified on the site, and a buyer should confirm every one of these terms on the live pages before relying on it.

It is worth being clear about why a site that will not load matters beyond the inconvenience. Our method depends on reading what a supplier says about itself: the certificate it links, the address it prints, the return terms it writes down. When those pages return an access error, every one of those checks fails, and the review has to be built from what other people have written. Some of those people are sponsored. Some run competing directories. Some are community wikis with no editorial process. Each of those sources can be right, and on points where they agree with the FDA record they appear to be, but none of them is the vendor, and a buyer should know that the picture here is second-hand throughout.

Set against the field, that puts PureRawz in a small group of active suppliers we could not evaluate from primary pages, and in a smaller group still that also carries a recent warning letter. The letter concerns products named in the letter rather than the peptide line, which some readers will treat as a distinction that matters. We record it as the agency recorded it, as a finding about the company’s conduct, and we note that the FDA’s rejection of the research-use labeling applies to the company’s whole approach rather than to one product category. Readers who want to know more should open the letter itself; it is short and specific.

Bottom line

A review of PureRawz is, for now, a review of what other people say about it, because the company’s own pages would not load for us. What can be verified is the September 2025 FDA warning letter and the address on it. What is reported is a named laboratory, a long operating history, a wide payment list, and independent test results that pass less than half the time alongside community reports of stale certificates. We would not order from a supplier we could not read and whose regulatory record is this recent. A buyer who proceeds anyway should insist on seeing the certificate for their specific batch and should expect the limits on returns that the third-party sources describe.